Full Press Release Details
CAMBRIDGE, Mass. , July 29, 2024 /PRNewswire/ -- Akebia Therapeutics ® , Inc. (Nasdaq: AKBA ), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced participation in two investor conferences in August: BTIG virtual Biotechnology Conference, August 5-6, 2024 , and Canaccord Genuity (CG) 44 th Annual Growth Conference, August 13-14, 2024 in Boston .
• BTIG Biotechnology Conference John Butler , Chief Executive Officer, will participate in a fireside chat on Tuesday, August 6 , at 8:00 am EST .
• CG 44 th Annual Growth Conference Mr. Butler will present on Wednesday, August 14 at 8:30 a.m . EST. A webcast of the presentation can be accessed through the "Investors" section of Akebia's website at https://ir.akebia.com following the conference.
About Akebia Therapeutics Akebia Therapeutics, Inc. is a fully integrated biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease. Akebia was founded in 2007 and is headquartered in Cambridge, Massachusetts . For more information, please visit our website at www.akebia.com , which does not form a part of this release.
Akebia Therapeutics Contact Mercedes Carrasco [email protected]